These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25800176)

  • 41. Fluorescence-guided Surgery with Splenic Preservation Prevents Tumor Recurrence in an Orthotopic Nude-mouse Model of Human Pancreatic Cancer.
    Hwang HK; Kang CM; Lee SH; Murakami T; Kiyuna T; Kim SH; Hoffman RM; Bouvet M
    Anticancer Res; 2018 Feb; 38(2):665-670. PubMed ID: 29374688
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A case of pancreatic cancer with local recurrence and liver metastases eight years after surgery].
    Taniguchi H; Mizuma M; Motoi F; Abe T; Okada R; Kawaguchi K; Karasawa H; Masuda K; Yabuuchi S; Fukase K; Sakata N; Okada T; Nakagawa K; Hayashi H; Morikawa T; Yoshida H; Naito T; Katayose Y; Egawa S; Unno M
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2193-5. PubMed ID: 25731467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model.
    Tepel J; Kruse ML; Kapischke M; Haye S; Sipos B; Kremer B; Kalthoff H
    Pancreatology; 2006; 6(3):240-7. PubMed ID: 16543775
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial.
    Davis JL; Pandalai P; Ripley RT; Langan RC; Steinberg SM; Walker M; Toomey MA; Levy E; Avital I
    Trials; 2011 May; 12():129. PubMed ID: 21595953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proof of Principle of Combining Fluorescence-Guided Surgery with Photoimmunotherapy to Improve the Outcome of Pancreatic Cancer Therapy in an Orthotopic Mouse Model.
    Nishino H; Turner MA; Amirfakhri S; Lwin TM; Hosseini M; Singer BB; Hoffman RM; Bouvet M
    Ann Surg Oncol; 2023 Jan; 30(1):618-625. PubMed ID: 36057899
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A Case of Gemcitabine Refractory Lung Metastasis after Distal Pancreatectomy for Pancreatic Cancer, Effectively Treated with S -1 as Second Line Chemotherapy].
    Omori K; Wakabayashi K; Suematsu Y; Suda H; Hiratsuka M; Takahashi M; Saito H; Ishibashi Y; Morita A; Ito Y
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1582-4. PubMed ID: 26805103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.
    Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Nelson SD; Dry SM; Li Y; Russell TA; Singh AS; Chmielowski B; Unno M; Eilber FC; Hoffman RM
    Cell Cycle; 2017 Jun; 16(11):1063-1069. PubMed ID: 28426279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX).
    Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Lwin TM; Hwang HK; Delong JC; Clary BM; Bouvet M; Unno M; Hoffman RM
    Oncotarget; 2017 Jul; 8(29):47490-47496. PubMed ID: 28537897
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft.
    Turner MA; Hollandsworth HM; Nishino H; Amirfakhri S; Lwin TM; Lowy AM; Kaur S; Natarajan G; Mallya K; Hoffman RM; Batra SK; Bouvet M
    In Vivo; 2022; 36(1):57-62. PubMed ID: 34972700
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody.
    Cox KE; Turner MA; Lwin TM; Amirfakhri S; Kelly KJ; Hosseini M; Ghosh P; Obonyo M; Hoffman RM; Yazaki PJ; Bouvet M
    Ann Surg Oncol; 2024 Sep; 31(9):6291-6299. PubMed ID: 38888861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Higuchi T; Kawaguchi K; Miyake K; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Igarashi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Nelson SD; Dry SM; Li Y; Chawla SP; Eilber FC; Singh SR; Tsuchiya H; Hoffman RM
    Biomed Pharmacother; 2019 Mar; 111():835-840. PubMed ID: 30616082
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of a patient with borderline resectable pancreatic cancer. Case report and review.
    Shah AP; Strauss JB; Leslie WT; Shah A; Mahon B; Abrams RA
    Oncology (Williston Park); 2008 Nov; 22(13):1524-9. PubMed ID: 19133606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model.
    Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1075-1082. PubMed ID: 30929053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
    Masui T; Doi R; Kawaguchi Y; Sato A; Nakano K; Ito T; Anazawa T; Takaori K; Uemoto S
    Surg Today; 2016 Nov; 46(11):1282-9. PubMed ID: 26860274
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Chemotherapy, chemoradiotherapy or observation after complete resection of pancreatic adenocarcinoma?].
    Lluís F
    Gastroenterol Hepatol; 2009 Feb; 32(2):120-1. PubMed ID: 19231687
    [No Abstract]   [Full Text] [Related]  

  • 56. [Local recurrence of pancreatic cancer successfully treated with gemcitabine].
    Ohmura T; Umekita N; Ohkubo T; Tanaka S; Maeshiro T; Matsuo S; Miyamoto S; Inoue S; Kitamura M
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):239-41. PubMed ID: 15751641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
    Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
    World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
    Satoi S; Yanagimoto H; Yamamoto T; Ohe C; Miyasaka C; Uemura Y; Hirooka S; Yamaki S; Ryota H; Michiura T; Inoue K; Matsui Y; Tanigawa N; Kon M
    Surg Today; 2017 Jan; 47(1):84-91. PubMed ID: 27262676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adenoviral targeting of malignant melanoma for fluorescence-guided surgery prevents recurrence in orthotopic nude-mouse models.
    Yano S; Takehara K; Kishimoto H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
    Oncotarget; 2016 Apr; 7(14):18558-72. PubMed ID: 26701857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Chemoradiation for pancreatic adenocarcinoma].
    Flandin I; Mornex F; Claude L; Kubas A; Khodri M; Wautot V; Mazeron R; Partensky C
    Cancer Radiother; 2004 Nov; 8 Suppl 1():S80-7. PubMed ID: 15679252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.